J
Jie Zhu
Researcher at University of Electronic Science and Technology of China
Publications - 7
Citations - 122
Jie Zhu is an academic researcher from University of Electronic Science and Technology of China. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications receiving 2 citations. Previous affiliations of Jie Zhu include Peking Union Medical College.
Papers
More filters
Journal ArticleDOI
One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China: A Longitudinal Cohort Study.
Yu-Hui Liu,Yang Chen,Qing-Hua Wang,Ling-Ru Wang,Li Jiang,Ying Yang,Xin Chen,Ying Li,Yuan Cen,Cheng Xu,Jie Zhu,Wei Li,Ye-Ran Wang,Li-Li Zhang,Juan Liu,Zhi-Qiang Xu,Yan-Jiang Wang +16 more
TL;DR: In this cohort study, COVID-19 survival was associated with an increase in risk of longitudinal cognitive decline, highlighting the importance of immediate measures to deal with this challenge.
Journal ArticleDOI
Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review.
Jie Zhu,Jie Zhu,Yong Yang,Jin Tao,Shu Lian Wang,Bo Chen,Jian Rong Dai,Chen Hu,Shu Nan Qi,Ye Xiong Li +9 more
TL;DR: PFS and EFS are recommended as earlier efficacy endpoints in patients with DLBCL primarily treated with rituximab-containing immunochemotherapy, and externally validated using independent phase II, and retrospective data.
Journal ArticleDOI
An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia
Weikaixin Kong,Liye He,Jie Zhu,Oscar Brück,Kimmo Porkka,Caroline A. Heckman,Sujie Zhu,Tero Aittokallio +7 more
TL;DR: In this article , an immunity and pyroptosis-related prognostic (IPRP) signature was developed for acute myeloid leukemia (AML) patients, which consists of 15 genes.
Journal ArticleDOI
Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review
TL;DR: Large-scale randomized controlled trials with strict quality control are identified and PFS is recommended as an early efficacy endpoint in resected esophageal or GEJ cancer treated with neoadjuvant therapy.
Journal ArticleDOI
Letter to the editor regarding the article ''Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma - A systematic review and meta-analysis" by Chow et al.
Jie Zhu,Yan Tan,Lifeng Wang +2 more
TL;DR: In this paper , a meta-analysis comparing definitive chemoradiotherapy with neoadjuvant chemordaotherapy and esophagectomy followed by surgery for esophageal and gastroesophageaal carcinoma was performed using literature-based evidence.